Recent Press Releases
May 2, 2013FDA Advisory Committee Unanimously Recommends JUVÉDERM VOLUMA™ XC as a Safe and Effective Treatment Option for Cheek Augmentation to Correct Age-Related Volume Deficit in the Mid-Face
May 2, 2013Study Results Published In Obesity From Data That Led The U.S. Food And Drug Administration To Approve The Expanded Use of The Lap-Band® Gastric Banding System
May 2, 2013New Guidelines Recommend Medical and Surgical Therapies Added to Overall Comprehensive Care Plan For Obese Patients with Type 2 Diabetes
May 1, 2013 Apr 24, 2013Allergan Welcomes 'Keogh Review' Recommendations to Classify All Cosmetic Implants as Medical Devices
Apr 16, 2013Allergan Receives Complete Response Letter from the U.S. Food and Drug Administration for LEVADEX® (dihydroergotamine) New Drug Application
Apr 3, 2013 Mar 1, 2013Allergan, Inc. Announces Expiration of Tender Offer for All Outstanding Shares of MAP Pharmaceuticals, Inc. and Intent to Exercise Top-Up Option to Effect a Short-Form Merger
Feb 20, 2013FDA Approves Natrelle® 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants
Feb 7, 2013Allergan, Inc. and MAP Pharmaceuticals, Inc. Announce the Federal Trade Commission Has Granted Early Termination of Waiting Period Under Hart-Scott-Rodino Act
Feb 5, 2013 Jan 31, 2013Allergan Commences Cash Tender Offer for All Outstanding Shares of MAP Pharmaceuticals
Jan 22, 2013 Jan 18, 2013BOTOX® (onabotulinumtoxinA) Receives U.S. Food and Drug Administration Approval for the Treatment of Overactive Bladder for Adults Who Have an Inadequate Response to or Are Intolerant of an Anticholinergic Medication
Jan 7, 2013 Dec 19, 2012Allergan, Inc. Announces Completion of SkinMedica, Inc. Acquisition
Dec 19, 2012Allergan's BOTOX® (botulinum toxin type A) Receives a Positive Opinion in Fourteen European Countries for Idiopathic Overactive Bladder
Nov 16, 2012 Oct 30, 2012 Oct 3, 2012| Showing 1-20 of 336 |
| Page: 1 2 3 ... 17 |
| Next 20 |